Hypertensive coronary microvascular dysfunction: a subclinical marker of end organ damage and heart failure.
Coronary microvascular dysfunction
Heart failure
Hypertension
Journal
European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263
Informations de publication
Date de publication:
01 07 2020
01 07 2020
Historique:
received:
28
01
2020
revised:
14
02
2020
accepted:
03
03
2020
pubmed:
30
3
2020
medline:
15
5
2021
entrez:
30
3
2020
Statut:
ppublish
Résumé
Hypertension is a well-established heart failure (HF) risk factor, especially in the context of adverse left ventricular (LV) remodelling. We aimed to use myocardial flow reserve (MFR) and global longitudinal strain (GLS), markers of subclinical microvascular and myocardial dysfunction, to refine hypertensive HF risk assessment. Consecutive patients undergoing symptom-prompted stress cardiac positron emission tomography (PET)-computed tomography and transthoracic echocardiogram within 90 days without reduced left ventricular ejection fraction (<40%) or flow-limiting coronary artery disease (summed stress score ≥ 3) were included. Global MFR was quantified by PET, and echocardiograms were retrospectively analysed for cardiac structure and function. Patients were followed over a median 8.75 (Q1-3 4.56-10.04) years for HF hospitalization and a composite of death, HF hospitalization, MI, or stroke. Of 194 patients, 155 had adaptive LV remodelling while 39 had maladaptive remodelling, which was associated with lower MFR and impaired GLS. Across the remodelling spectrum, diastolic parameters, GLS, and N-terminal pro-B-type natriuretic peptide were independently associated with MFR. Maladaptive LV remodelling was associated with increased adjusted incidence of HF hospitalization and death. Importantly, the combination of abnormal MFR and GLS was associated with a higher rate of HF hospitalization compared to normal MFR and GLS [adjusted hazard ratio (HR) 3.21, 95% confidence interval (CI) 1.09-9.45, P = 0.034), including in the adaptive remodelling subset (adjusted HR 3.93, 95% CI 1.14-13.56, P = 0.030). We have demonstrated important associations between coronary microvascular dysfunction and myocardial mechanics that refine disease characterization and HF risk assessment of patients with hypertension based on subclinical target organ injury.
Identifiants
pubmed: 32221588
pii: 5813079
doi: 10.1093/eurheartj/ehaa191
pmc: PMC7327534
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2366-2375Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL135438
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL159276
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL094301
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007604
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.
Références
J Am Coll Cardiol. 2010 Jan 12;55(2):91-6
pubmed: 20117376
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264
pubmed: 30153967
Circulation. 2020 Jan 7;141(1):21-33
pubmed: 31779467
N Engl J Med. 1988 Nov 17;319(20):1302-7
pubmed: 3185633
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Circulation. 2011 Nov 15;124(20):2215-24
pubmed: 22007073
Circ Cardiovasc Imaging. 2012 Nov;5(6):700-7
pubmed: 23051888
J Am Heart Assoc. 2018 Feb 8;7(4):
pubmed: 29437599
J Card Fail. 2008 Oct;14(8):687-94
pubmed: 18926441
Circulation. 2011 Jan 25;123(3):327-34
pubmed: 21263005
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
JACC Cardiovasc Imaging. 2015 Feb;8(2):210-20
pubmed: 25677893
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
J Nucl Cardiol. 2019 May 1;:
pubmed: 31044406
N Engl J Med. 2015 Nov 26;373(22):2103-16
pubmed: 26551272
J Am Coll Cardiol. 2006 Mar 7;47(5):1043-8
pubmed: 16516091
JACC Cardiovasc Imaging. 2009 Jan;2(1):80-4
pubmed: 19356538
J Am Coll Cardiol. 2012 Sep 11;60(11):960-8
pubmed: 22921971
JAMA. 1996 May 22-29;275(20):1557-62
pubmed: 8622246
Circulation. 2003 Mar 11;107(9):1284-90
pubmed: 12628949
Eur Heart J. 2018 Mar 7;39(10):840-849
pubmed: 29293969
J Am Coll Cardiol. 2011 Mar 15;57(11):1271-9
pubmed: 21392641
Diabetes. 2016 Oct;65(10):3129-38
pubmed: 27352886
Diabetes. 2015 Jan;64(1):236-42
pubmed: 25125488
J Am Coll Cardiol. 2018 Aug 14;72(7):707-717
pubmed: 30092946
N Engl J Med. 2007 Feb 22;356(8):830-40
pubmed: 17314342
Eur Heart J. 2018 Oct 1;39(37):3439-3450
pubmed: 30165580
Circ Cardiovasc Imaging. 2015 Jan;8(1):
pubmed: 25596143
J Am Coll Cardiol. 2019 Dec 10;74(23):2858-2873
pubmed: 31806129
Circulation. 2001 Aug 7;104(6):735-40
pubmed: 11489784
Eur Heart J. 2013 Oct;34(38):2949-3003
pubmed: 23996286
Eur Heart J. 2020 Jan 14;41(3):407-477
pubmed: 31504439
J Nucl Med. 2009 Jul;50(7):1062-71
pubmed: 19525467
Circulation. 2012 Oct 9;126(15):1858-68
pubmed: 22919001